(DNLI) Denali Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24823R1059

Stock: Neuro Drugs, Enzyme Therapy, Genetic Disorders

Total Rating 38
Risk 84
Buy Signal -0.58
Biotechnology +8.2
Biotechnology +8.2
Market Cap: 3,284m
Avg Trading Vol: 29.2M USD
ATR: 5.53%
Peers RS (IBD): 38.8
Risk 5d forecast
Volatility 60.8%
Relative Tail Risk -8.96%
Reward TTM
Sharpe Ratio 0.71
Alpha 3.80
Character TTM
Beta 1.895
Beta Downside 1.502
Drawdowns 3y
Max DD 65.20%
CAGR/Max DD -0.07

EPS (Earnings per Share)

EPS (Earnings per Share) of DNLI over the last years for every Quarter: "2021-03": -0.58, "2021-06": -0.5, "2021-09": -0.69, "2021-12": -0.62, "2022-03": -0.53, "2022-06": -0.48, "2022-09": -0.84, "2022-12": -0.75, "2023-03": -0.8, "2023-06": 1.3, "2023-09": -0.72, "2023-12": -0.86, "2024-03": -0.78, "2024-06": -0.59, "2024-09": -0.63, "2024-12": -0.67, "2025-03": -0.78, "2025-06": -0.72, "2025-09": -0.74, "2025-12": -0.73,
EPS CAGR: -16.68%
EPS Trend: -18.7%
Last SUE: 0.22
Qual. Beats: 0

Revenue

Revenue of DNLI over the last years for every Quarter: 2021-03: 7.923, 2021-06: 22.939, 2021-09: 5.285, 2021-12: 12.514, 2022-03: 42.141, 2022-06: 52.48, 2022-09: 3.559, 2022-12: 10.283, 2023-03: 35.141, 2023-06: 294.123, 2023-09: 1.267, 2023-12: -305.043, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: -3.39%
Rev. Trend: -55.3%
Last SUE: -0.40
Qual. Beats: 0

Risks

Technicals: choppy

Description: DNLI Denali Therapeutics March 05, 2026

Denali Therapeutics Inc. (DNLI) is a biotechnology company focused on neurodegenerative and lysosomal storage diseases. The biotechnology sector is characterized by extensive research and development phases for new drug candidates.

Denalis pipeline includes Eclitasertib for inflammatory diseases, DNL343 for amyotrophic lateral sclerosis, and BIIB122/DNL151 for Parkinsons disease. Their business model involves developing novel therapies, often through strategic partnerships.

The company also utilizes Enzyme Transport Vehicle (TV) programs for conditions like Pompe disease and Parkinsons, and Antibody TV programs for Alzheimers disease. For more in-depth analysis of their drug pipeline and market position, consider researching further on ValueRay.

Headlines to watch out for

  • Clinical trial results for Parkinsons disease program impact stock
  • Regulatory approval of lead drug candidates drives valuation
  • Partnerships with larger pharmaceutical companies provide funding
  • Competition from other neurodegenerative disease treatments affects market share

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.37 > 0.02 and ΔFCF/TA -10.41 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.36 > 3% & CFO -412.6m > Net Income -512.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.16 > 1.5 & < 3
Outstanding Shares: last quarter (175.5m) vs 12m ago 3.16% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -16.08 > 6 (EBITDA TTM -531.6m / Interest Expense TTM -34.0m)

Altman Z'' -15.00

A: 0.70 (Total Current Assets 900.7m - Total Current Liabilities 98.4m) / Total Assets 1.14b
B: -1.79 (Retained Earnings -2.05b / Total Assets 1.14b)
C: -0.43 (EBIT TTM -546.4m / Avg Total Assets 1.26b)
D: -15.63 (Book Value of Equity -2.05b / Total Liabilities 131.1m)
Altman-Z'' Score: -20.57 = D

Beneish M

DSRI: none (Receivables 2.18m/2.17m, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 0.39 (AQ_t 0.11 / AQ_t-1 0.28)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.09 (NI -512.5m - CFO -412.6m) / TA 1.14b)
Beneish M-Score: cannot calculate (missing components)

What is the price of DNLI shares?

As of March 20, 2026, the stock is trading at USD 19.75 with a total of 1,370,895 shares traded.
Over the past week, the price has changed by -4.59%, over one month by -2.42%, over three months by +17.21% and over the past year by +33.27%.

Is DNLI a buy, sell or hold?

Denali Therapeutics has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy DNLI.
  • StrongBuy: 15
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the DNLI price?

Issuer Target Up/Down from current
Wallstreet Target Price 32.9 66.7%
Analysts Target Price 32.9 66.7%

DNLI Fundamental Data Overview March 18, 2026

P/S = 3643.6484
P/B = 3.2179
Revenue TTM = 0.0 USD
EBIT TTM = -546.4m USD
EBITDA TTM = -531.6m USD
Long Term Debt = 36.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.55m USD (from shortTermDebt, last quarter)
Debt = 42.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -163.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.46b USD (3.28b + Debt 42.3m - CCE 867.9m)
Interest Coverage Ratio = -16.08 (Ebit TTM -546.4m / Interest Expense TTM -34.0m)
EV/FCF = -5.83x (Enterprise Value 2.46b / FCF TTM -422.1m)
FCF Yield = -17.17% (FCF TTM -422.1m / Enterprise Value 2.46b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 107.9m) / Revenue TTM)
Tobins Q-Ratio = 2.15 (Enterprise Value 2.46b / Total Assets 1.14b)
Interest Expense / Debt = 49.85% (Interest Expense 21.1m / Debt 42.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -431.7m (EBIT -546.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.16 (Total Current Assets 900.7m / Total Current Liabilities 98.4m)
Debt / Equity = 0.04 (Debt 42.3m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -163.0m / EBITDA -531.6m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -163.0m / FCF TTM -422.1m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -40.69% (Net Income -512.5m / Total Assets 1.14b)
RoE = -50.13% (Net Income TTM -512.5m / Total Stockholder Equity 1.02b)
RoCE = -51.59% (EBIT -546.4m / Capital Employed (Equity 1.02b + L.T.Debt 36.8m))
RoIC = -42.22% (negative operating profit) (NOPAT -431.7m / Invested Capital 1.02b)
WACC = 13.24% (E(3.28b)/V(3.33b) * Re(12.90%) + D(42.3m)/V(3.33b) * Rd(49.85%) * (1-Tc(0.21)))
Discount Rate = 12.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.66%
[DCF] Fair Price = unknown (Cash Flow -422.1m)
EPS Correlation: -18.72 | EPS CAGR: -16.68% | SUE: 0.22 | # QB: 0
Revenue Correlation: -55.35 | Revenue CAGR: -3.39% | SUE: -0.40 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.58 | Chg7d=-0.022 | Chg30d=+0.043 | Revisions Net=+3 | Analysts=11
EPS current Year (2026-12-31): EPS=-2.68 | Chg7d=+0.009 | Chg30d=+0.258 | Revisions Net=+2 | Growth EPS=+9.8% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.48 | Chg7d=-0.008 | Chg30d=+0.057 | Revisions Net=+0 | Growth EPS=+7.4% | Growth Revenue=+163.4%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)

Additional Sources for DNLI Stock

Fund Manager Positions: Dataroma | Stockcircle